Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J, Stickeler E, Simon E, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S; German Breast Group Investigators. von Minckwitz G, et al. Among authors: thomssen c. Cancer. 2015 Oct 15;121(20):3639-48. doi: 10.1002/cncr.29506. Epub 2015 Jun 25. Cancer. 2015. PMID: 26111104 Free article. Clinical Trial.
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group. Jänicke F, et al. Among authors: thomssen c. J Natl Cancer Inst. 2001 Jun 20;93(12):913-20. doi: 10.1093/jnci/93.12.913. J Natl Cancer Inst. 2001. PMID: 11416112 Clinical Trial.
Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V, Witzel I, Lück HJ, Köhler G, von Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, Pantel K, Thomssen C. Müller V, et al. Among authors: thomssen c. Breast Cancer Res Treat. 2004 Jul;86(1):9-18. doi: 10.1023/B:BREA.0000032919.83803.48. Breast Cancer Res Treat. 2004. PMID: 15218357 Clinical Trial.
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Konecny GE, Thomssen C, Lück HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Möbus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Jänicke F, Slamon DJ. Konecny GE, et al. Among authors: thomssen c. J Natl Cancer Inst. 2004 Aug 4;96(15):1141-51. doi: 10.1093/jnci/djh198. J Natl Cancer Inst. 2004. PMID: 15292386
Anthracycline and trastuzumab in breast cancer treatment.
Untch M, Himsl I, Kahlert S, Lueck HJ, Eidtmann H, Du Bois A, Meerpohl HG, Thomssen C, Harbeck N, Jackisch C, Kreienberg R, Emons G, Wallwiener D, Wiese W, Schaller G, Kuhn W, Muscholl M, Pauschinger M, Langer B. Untch M, et al. Among authors: thomssen c. Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):59-64. Oncology (Williston Park). 2004. PMID: 15685838 Free article. Clinical Trial.
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC.
von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N, Kleeberg U, Tsekov C, Fritze D, Thomssen C, Stuart N, Vermorken JB, Loibl S, Merkle Kh, Kaufmann M. von Minckwitz G, et al. Among authors: thomssen c. Anticancer Drugs. 2005 Sep;16(8):871-7. doi: 10.1097/01.cad.0000175587.31940.19. Anticancer Drugs. 2005. PMID: 16096436 Clinical Trial.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Piccart-Gebhart MJ, et al. Among authors: thomssen c. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. N Engl J Med. 2005. PMID: 16236737 Free article. Clinical Trial.
Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer.
Frickhofen N, Berdel WE, Opri F, Haas R, Schneeweiss A, Sandherr M, Kuhn W, Hossfeld DK, Thomssen C, Heimpel H, Kreienberg R, Hinke A, Möbus V; German Study Groups Arbeitsgemeinschaft Internistische Onkologie (AIO); Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). Frickhofen N, et al. Among authors: thomssen c. Bone Marrow Transplant. 2006 Oct;38(7):493-9. doi: 10.1038/sj.bmt.1705472. Epub 2006 Aug 21. Bone Marrow Transplant. 2006. PMID: 16980997 Clinical Trial.
332 results